Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA499386
Max Phase: Preclinical
Molecular Formula: C70H103N17O20S2
Molecular Weight: 1566.83
Molecule Type: Protein
Associated Items:
ID: ALA499386
Max Phase: Preclinical
Molecular Formula: C70H103N17O20S2
Molecular Weight: 1566.83
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)CSSC[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)O)NC1=O
Standard InChI: InChI=1S/C70H103N17O20S2/c1-6-36(3)54-64(101)81-47(60(97)77-44(30-39-15-9-8-10-16-39)66(103)85-26-12-18-49(85)62(99)78-45(69(106)107)31-53(92)93)34-108-109-35-48(80-57(94)42(75-52(91)32-71)17-11-25-74-70(72)73)61(98)84-56(38(5)89)65(102)76-43(29-40-21-23-41(90)24-22-40)58(95)79-46(33-88)59(96)83-55(37(4)7-2)68(105)87-28-14-20-51(87)67(104)86-27-13-19-50(86)63(100)82-54/h8-10,15-16,21-24,36-38,42-51,54-56,88-90H,6-7,11-14,17-20,25-35,71H2,1-5H3,(H,75,91)(H,76,102)(H,77,97)(H,78,99)(H,79,95)(H,80,94)(H,81,101)(H,82,100)(H,83,96)(H,84,98)(H,92,93)(H,106,107)(H4,72,73,74)/t36-,37-,38+,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,54-,55-,56-/m0/s1
Standard InChI Key: FKOUGSRQBWXCPR-XNFZKIEOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1566.83 | Molecular Weight (Monoisotopic): 1565.7007 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Łegowska A, Debowski D, Lesner A, Wysocka M, Rolka K.. (2009) Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors., 17 (9): [PMID:19362846] [10.1016/j.bmc.2009.03.045] |
Source(1):